Impact of Biochemical Failure After Salvage Radiation Therapy on Prostate Cancer-specific Mortality: Competition Between Age and Time to Biochemical Failure.

[1]  M. Cooperberg,et al.  A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. , 2018, European urology.

[2]  P. Carroll,et al.  Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate Cancer. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  David C. Miller,et al.  Anatomical patterns of recurrence following biochemical relapse after post‐prostatectomy salvage radiation therapy: a multi‐institutional study , 2017, BJU international.

[4]  M. Cooperberg,et al.  The CAPRA Score at 10 Years: Contemporary Perspectives and Analysis of Supporting Studies. , 2017, European urology.

[5]  B. Trock,et al.  Individual Patient-Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High-Risk Men After Prostatectomy to Predict Development of Metastatic Disease. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Mehra,et al.  Very Early Salvage Radiotherapy Improves Distant Metastasis‐Free Survival , 2017, The Journal of urology.

[7]  D. Grignon,et al.  Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer , 2017, The New England journal of medicine.

[8]  J. Adolfsson,et al.  Cancer Specific Mortality in Men Diagnosed with Prostate Cancer before Age 50 Years: A Nationwide Population Based Study , 2017, The Journal of urology.

[9]  David Gillatt,et al.  10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. , 2017, The New England journal of medicine.

[10]  Adam P Dicker,et al.  Development and validation of a 24-gene predictor of response to postoperative radiotherapy in prostate cancer: a matched, retrospective analysis. , 2016, The Lancet. Oncology.

[11]  Shree Agrawal,et al.  Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Sean S. Park,et al.  Recurrence Patterns of Oligometastatic Disease Detected Using C-11 Choline Positron Emission Tomography/Computed Tomography in Patients With a Rising Prostate-Specific Antigen Level Following Postprostatectomy Radiation Therapy , 2016 .

[13]  W. Harmsen,et al.  Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  B. Dubray,et al.  Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial. , 2016, The Lancet. Oncology.

[15]  U. Capitanio,et al.  Predicting survival of men with recurrent prostate cancer after radical prostatectomy. , 2016, European journal of cancer.

[16]  D. Grignon,et al.  NRG Oncology/RTOG 9601, a phase III trial in prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. , 2016 .

[17]  D. Tindall,et al.  Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. , 2015, Cancer research.

[18]  M. Kattan,et al.  Nomogram Predicting Prostate Cancer-specific Mortality for Men with Biochemical Recurrence After Radical Prostatectomy. , 2015, European urology.

[19]  E. Klein,et al.  High-throughput transcriptomic analysis nominates proteasomal genes as age-specific biomarkers and therapeutic targets in prostate cancer , 2015, Prostate Cancer and Prostatic Disease.

[20]  W. Jackson,et al.  A comprehensive assessment of the prognostic utility of the Stephenson nomogram for salvage radiation therapy postprostatectomy. , 2014, Practical radiation oncology.

[21]  H. Hieronymus,et al.  Androgen receptor signaling regulates DNA repair in prostate cancers. , 2013, Cancer discovery.

[22]  E. Messing,et al.  Prostate cancer in the elderly , 2012, Cancer.

[23]  Yongmei Chen,et al.  Prostate cancer in men 70 years old or older, indolent or aggressive: clinicopathological analysis and outcomes. , 2011, The Journal of urology.

[24]  D. Lin,et al.  Treatment and survival outcomes in young men diagnosed with prostate cancer , 2009, Cancer.

[25]  E. Messing,et al.  Predominant treatment failure in postprostatectomy patients is local: analysis of patterns of treatment failure in SWOG 8794. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  M. Kattan,et al.  Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. , 2006, Journal of the National Cancer Institute.

[27]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[28]  Crawford,et al.  Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials , 2000, The Lancet.

[29]  I. Thompson,et al.  Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. , 1998, The New England journal of medicine.

[30]  C. Huggins.  Endocrine-induced regression of cancers. , 1967, American journal of surgery.